A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma

NCT01718327 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Unresectable and Advanced Cholangiocarcinoma

Interventions

DRUG: Sunitinib

Sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group